Beyond Air, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Beyond Air (XAIR) agreed to sell its 58% stake in NeuroNOS to UNIVO for equity and milestone payments. Beyond Air will receive 19.99% of UNIVO's shares and warrants, plus up to $32.5M in milestone payments. XAIR closed at $4.91, down 2.58%.
Lucid Group (LCID), Beyond Air (XAIR), and Conagra Brands (CAG) hit 52-week lows. LCID's outlook weakened due to lower revenue expectations and a stock offering, with analysts cutting price targets. XAIR received a Nasdaq compliance notice, while CAG faces earnings pressure from inflation and a recent CEO change.
Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement fo
Over the past 7 days, alphai's AI scored 2 news stories mentioning XAIR (Beyond Air, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent XAIR coverage spans earnings, market movers and insider activity.
In the last 30 days, XAIR insiders filed 2 SEC Form 4 transactions — 2 purchases ($225K) and no sales. The most active reporter was Goodman Robert Scott, Chief Executive Officer, with 1 filing.
The deal dilutes existing shareholders but provides cashless equity and potential upside from UNIVO performance.
Risk of delisting creates bearish pressure.
The filing adds a concrete capital raise and keeps revenue guidance anchored to an FDA decision window, shifting near-term risk toward regulatory timing and funding runway.
Near-term valuation hinges on FDA review timing for Gen II LungFit PH and the company’s ability to convert contracting momentum into post-approval revenue.
Near-term catalyst is FDA review timing for the second-generation LungFit PH PMA supplement, plus dilution/financing details supporting launch readiness.
alphai scores every news story that mentions XAIR with an AI model for sentiment and relevance, and aggregates insider trades from Beyond Air, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Beyond Air (XAIR) agreed to sell its 58% stake in NeuroNOS to UNIVO for equity and milestone payments. Beyond Air will receive 19.99% of UNIVO's shares and warrants, plus up to $32.5M in milestone payments. XAIR closed at $4.91, down 2.58%.
2 min readLucid Group (LCID), Beyond Air (XAIR), and Conagra Brands (CAG) hit 52-week lows. LCID's outlook weakened due to lower revenue expectations and a stock offering, with analysts cutting price targets. XAIR received a Nasdaq compliance notice, while CAG faces earnings pressure from inflation and a recent CEO change.
2 min readBeyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement fo
6 min readBeyond Air (XAIR) held a Q1 2027 earnings call. It reported Q ended June 30, 2026 revenue of $1.8 million, flat vs the prior quarter, with gross margin rising to 13% from 9%. The company reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, pending FDA approval for its Gen II LungFit PH system. It also entered a national GPO deal and announced financing up to $30 million.
6 min readBeyond Air (NASDAQ: XAIR) reported Q2 2026 revenue of $1.8 million and gross margin of 13%. It reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million, including second-generation LungFit PH revenue pending FDA approval. The company is awaiting FDA review of a PMA supplement, expects a decision in 2H 2026, and raised up to $30.1 million.
6 min readBiotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
3 min readGoodman Robert Scott (Chief Executive Officer) purchased 34,722 shares of Beyond Air, Inc. (XAIR) at $5.76 ($0.20M total) on 2026-07-29.
2 min readMOORHEAD DANIEL J (Chief Financial Officer) purchased 4,340 shares of Beyond Air, Inc. (XAIR) at $5.76 on 2026-07-29.
2 min readBeyond Air, Inc. (XAIR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules Beyond Air™ $10.2 million upfront with up to $10.0 million of short-term warrants, accelerated upon FDA clearance; financing also includes an additional $10.0
4 min readBeyond Air (XAIR) reported fiscal 2026 revenue of $7.7 million (+107%) and Q4 revenue of $1.9 million (+66%). Management cited ~90% customer renewal and expects CY 2026 revenue guidance of $8 million and CY 2027 of $16–$18 million. Gross profit was $0.3 million vs a prior-year loss; net loss was $33.2 million. The company also approved a 1-for-20 reverse stock split and guided on Gen 2 regulatory approval as a key catalyst.
6 min read
